Mohammed Azib M Alqahtani is a Boston, Massachusetts based neurologist who is specialized in Child Neurology. Active license number of Mohammed Azib M Alqahtani is 3017839 for Epilepsy Treatment in Massachusetts. His current practice location is 300 Longwood Ave # Fegan11, Boston. Patients can reach him at 617-355-8735. Mohammed Azib M Alqahtani NPI number (Unique professional ID assigned by NPPES) is 1104718402. Mohammed Azib M Alqahtani specializes in neurology with special skills in diagnosis and treatment of neurologic disorders of the neonatal period, infancy, early childhood, and adolescence.
Complete Profile:
Mohammed Azib M Alqahtani speciality, credentials, practice address, contact phone number and fax are as below.
Patients can call on the below given phone number for appointment.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1104718402
NPI Enumeration Date:
19 Jul, 2025
NPI Last Update On:
19 Jul, 2025
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mohammed Azib M Alqahtani are as mentioned below.
License Number
Specialization
State
Status
3017839
Epilepsy Treatment
Massachusetts
Primary
3017839
Child Neurology
Massachusetts
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
Mohammed Azib M Alqahtani 300 Longwood Ave # Fegan11, Boston, Massachusetts
Zip:
02115-5724
Phone Number:
617-355-8735
Patients can reach Mohammed Azib M Alqahtani at 300 Longwood Ave # Fegan11, Boston, Massachusetts or can call to book an appointment on 617-355-8735.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.